Pariza George, Mavrodin Carmen, Potorac Alina, Munteanu Octavian, Cîrstoiu Monica Mihaela
Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
5th Department of General Surgery, Emergency Hospital Bucharest, 050098 Bucharest, Romania.
Life (Basel). 2025 Aug 20;15(8):1318. doi: 10.3390/life15081318.
The objective of this paper is to define "poor candidates" and to conduct an analysis of preoperative selection criteria, considering factors related to the patient, tumor burden, and histopathological characteristics, in the case of patients with advanced epithelial ovarian cancer (EOC) FIGO III-IV with a low probability of optimal cytoreduction. The authors of this narrative review conducted an analysis of articles published over a 20-year period (2005-2025), with the following selection criteria for the topics of the papers: advanced epithelial ovarian cancer (FIGOIII-IV), surgical indications in advanced ovarian cancer, poor candidates for surgery, and dependence between surgery and histopathologic and molecular type of EOC. They used using PubMed, Science Direct, and Scopus as databases. The results of the analysis were organized into three large chapters that grouped patient-related factors, tumor burden-specific factors, and histopathological criteria. The authors identify a series of criteria with a high risk of unfavorable postoperative evolution, which led to delayed chemotherapy treatment and suboptimal management. These criteria are related to the patient's field (ECOG > 3, Charlson Comorbidity Index (CCI) > 2, BMI > 25-30, hypoalbuminemia, hypokalemia), imaging or intraoperative factors predictive for residual tumor, and histopathological or genetic factors (presence of BRCA mutation favors optimal cytoreduction even in cases with high tumor burden; in the case of low-grade serous ovarian carcinoma, surgical intervention is recommended even if there are suboptimal resection criteria, accepting resection > 1 cm due to the poor response to specific chemotherapy treatment). Considering all these aspects, patient selection for primary debulking surgery (PDS) or NACT (neoadjuvant chemotherapy) and interval debulking surgery (IDS) should be conducted in oncological surgery centers highly specialized in gynecological neoplasms, thus ensuring an optimal therapeutic pathway for patients with EOC.
本文的目的是定义“不佳候选者”,并对术前选择标准进行分析,考虑与患者、肿瘤负荷和组织病理学特征相关的因素,针对国际妇产科联盟(FIGO)III-IV期晚期上皮性卵巢癌(EOC)且最佳肿瘤细胞减灭可能性较低的患者。这篇叙述性综述的作者对20年期间(2005年至2025年)发表的文章进行了分析,对文章主题有以下选择标准:晚期上皮性卵巢癌(FIGO III-IV)、晚期卵巢癌的手术指征、手术不佳候选者以及EOC手术与组织病理学和分子类型之间的相关性。他们使用PubMed、ScienceDirect和Scopus作为数据库。分析结果被整理成三大章,分别归类了与患者相关的因素、肿瘤负荷特异性因素和组织病理学标准。作者确定了一系列术后转归不佳风险较高的标准,这些标准导致化疗延迟和管理欠佳。这些标准与患者方面(东部肿瘤协作组体能状态评分(ECOG)>3、查尔森合并症指数(CCI)>2、体重指数(BMI)>25-30、低白蛋白血症、低钾血症)、预测残留肿瘤的影像学或术中因素以及组织病理学或遗传因素有关(BRCA突变的存在有利于即使在肿瘤负荷高的情况下实现最佳肿瘤细胞减灭;在低级别浆液性卵巢癌的情况下,即使存在切除不充分的标准,也建议进行手术干预,因对特定化疗治疗反应不佳而接受>1 cm的切除)。考虑到所有这些方面,对于原发性肿瘤细胞减灭术(PDS)或新辅助化疗(NACT)以及中间性肿瘤细胞减灭术(IDS)的患者选择,应在高度专业化的妇科肿瘤肿瘤外科中心进行,从而确保为EOC患者提供最佳治疗途径。